Alzheimer's disease affects an estimated 55 million people worldwide and that number is projected to nearly double by 2050. With no cure and limited treatment options, researchers have been searching for compounds that could slow cognitive decline or protect the brain from the deterioration associated with the disease.
Methylene blue has been one of the more studied candidates in this space for over a decade. The research is more advanced than most people realise, including a large-scale Phase 3 clinical trial that published results in January 2026. This post covers what the science actually shows, where the evidence is strong, where it is still emerging and what it all means for people researching methylene blue for brain health.
Heisen Blue products are sold strictly for research purposes and are not intended to diagnose, treat, cure or prevent any disease.
Why Alzheimer's Researchers Are Interested in Methylene Blue
To understand why methylene blue is relevant to Alzheimer's research, it helps to understand what Alzheimer's actually does to the brain at a biological level.
Alzheimer's is characterized by two key hallmarks: the buildup of amyloid-beta plaques between neurons and the tangling of tau proteins inside neurons. Both disrupt normal brain function. Beyond these structural changes, Alzheimer's involves significant mitochondrial dysfunction, meaning the brain's cells lose their ability to produce energy efficiently. Oxidative stress and neuroinflammation also accelerate the damage.
Methylene blue addresses several of these mechanisms simultaneously which is why it has attracted serious scientific attention:
Tau inhibition. Methylene blue inhibits the aggregation of tau proteins, one of the primary pathological processes in Alzheimer's disease. This is now well established in both animal models and is the basis for the clinical trials discussed below.
Amyloid-beta reduction. Research has shown methylene blue can reduce the accumulation of amyloid-beta plaques in animal models, though this finding is less consistent in human trials.
Mitochondrial support. The mitochondrial dysfunction that drives much of Alzheimer's cognitive decline is directly relevant to methylene blue's documented role as an alternative electron carrier in the energy production chain. Healthy mitochondria mean more energy for neurons to function correctly.
Antioxidant properties. Methylene blue reduces reactive oxygen species which are the unstable molecules that damage neurons and accelerate cognitive decline.
Blood-brain barrier crossing. Methylene blue crosses the blood-brain barrier efficiently and accumulates preferentially in brain tissue. This is not a minor advantage. Many potentially useful compounds simply cannot reach the brain in meaningful concentrations.
The Largest Clinical Trial: LUCIDITY
The most significant human research on methylene blue and Alzheimer's comes from TauRx Therapeutics, a company founded specifically to investigate methylene blue derivatives for neurodegenerative disease. Their compound is called HMTM, which stands for hydromethylthionine mesylate, a stabilized derivative of methylene blue.
It is important to be clear about this distinction upfront. HMTM is derived from methylene blue and shares its core mechanisms but is not identical to the methylene blue sold as a research compound used for biohackers. The findings from TauRx trials are relevant context for understanding methylene blue's potential in this area but they do not directly translate to claims about what methylene blue supplements do.
The LUCIDITY trial enrolled 598 participants with mild cognitive impairment or mild to moderate Alzheimer's disease. Participants were randomized to three groups: a control group receiving a very low dose, a group receiving 8mg per day of HMTM and a group receiving 16mg per day of HMTM. The trial ran for 12 months in the blinded phase followed by an open-label extension.
What the overall trial found:
The trial did not meet its co-primary endpoints for the full study population. This is an important fact to acknowledge upfront. The overall results for the combined MCI and mild to moderate Alzheimer's population did not show statistically significant differences at the primary measures of cognitive and functional decline compared to the control group.
What the subgroup findings showed:
Within the subgroup of participants with mild cognitive impairment specifically, the results were considerably more encouraging. Published in the Journal of Prevention of Alzheimer's Disease in January 2026, the findings showed that participants with MCI who received 16mg per day of HMTM experienced:
- Statistically significant cognitive improvement sustained over 18 months
- No significant cognitive or functional decline observed over a full two years
- A 48% lower rate of progression from mild cognitive impairment to dementia diagnosis at 12 months compared to the control group
- A 93% reduction in the change of neurofilament light chain, a biomarker of brain neurodegeneration, over 12 months
- 71% of treated patients had the same or better global rating after two years compared to 52% in the control group
At the AD/PD 2025 conference in Vienna, TauRx presented further analysis confirming the efficacy of HMTM in reducing clinical decline and brain atrophy progression in early Alzheimer's over a 78-week period.
TauRx has submitted a marketing authorisation application to the UK's Medicines and Healthcare products Regulatory Agency. As of mid 2026 that application is still under review.
The Dose Finding That Changes Everything
One of the most significant and underreported findings from the TauRx trials is what happened with the low-dose control group.
Because methylene blue discolours urine blue, it is extremely difficult to run a true placebo-controlled trial. Participants would immediately know whether they were receiving the compound or not. TauRx addressed this by giving the control group a very low dose of approximately 4mg per week of methylthioninium chloride, on the assumption this was too small to produce any biological effect.
It was not.
The low-dose control group showed biological activity. What was supposed to be a placebo turned out to be an active dose. Later work confirmed that the very low doses selected as controls were likely biologically active.
This finding is consistent with everything the research on methylene blue suggests about the hormetic dose-response curve. The benefits cluster at low doses. Higher doses in earlier TauRx trials of 69mg, 138mg and 228mg per day showed no benefits. The 16mg per day dose in LUCIDITY showed meaningful benefits for MCI patients. The much lower control doses showed some biological activity. The pattern is remarkably consistent.
What Earlier Research Showed
Before LUCIDITY, earlier randomized controlled trials published in the Journal of Alzheimer's Disease found improvements in cognitive performance and reductions in brain volume loss in participants receiving methylene blue derivatives compared to controls. These earlier findings established the scientific rationale that LUCIDITY was designed to test at larger scale.
A 2023 comprehensive review published in Cureus by researchers from Michigan State University reviewed all randomised controlled trials on methylene blue and Alzheimer's treatment to that point. The review found that methylene blue demonstrated improvements in cognitive function, reductions in amyloid-beta plaque accumulation and antioxidant properties that reduced oxidative stress in the brain. Read the review
What This Means for Brain Health Researchers/Biohackers
The Alzheimer's research on methylene blue is more advanced than most people realize. A compound that has just completed a 598-person Phase 3 trial and achieved statistically significant results in a clinically meaningful subgroup is not fringe science. It is serious pharmaceutical research that happens to be studying a compound that has been around since 1876.
For people researching methylene blue for general brain health and cognitive support, the Alzheimer's research is relevant as context. The mechanisms being studied in Alzheimer's trials, tau inhibition, amyloid reduction, mitochondrial support and antioxidant activity, are the same mechanisms that researchers investigate when they look at methylene blue for everyday cognitive performance.
The key takeaway from all of this research combined is the same message that appears throughout the methylene blue literature: the effects are dose dependent and the benefits appear to cluster at lower doses. The 16mg per day dose that showed meaningful results in MCI patients in the LUCIDITY trial sits well within the typical range used by the broader research/biohacking community.
Important Caveats
HMTM is not identical to methylene blue. The TauRx trials tested a stabilized derivative compound. While the mechanisms overlap, the findings cannot be directly applied to methylene blue research compounds.
The LUCIDITY trial failed its primary endpoints for the full study population. The positive findings come from the MCI subgroup analysis. Subgroup analyses can be compelling but carry less statistical weight than primary endpoint results.
This research is ongoing. TauRx's marketing application is still under regulatory review. No methylene blue compound is approved for Alzheimer's treatment anywhere in the world as of mid 2026.
None of this constitutes medical advice. If you or someone you know is experiencing cognitive decline, please consult a qualified medical professional. Methylene blue is not an approved treatment for Alzheimer's disease or any other neurological condition.
Key Takeaways
- Methylene blue inhibits tau aggregation and reduces amyloid-beta, addressing two of Alzheimer's core pathological features
- The largest trial ever conducted on a methylene blue derivative, the 598-person LUCIDITY trial, published results in January 2026 showing significant cognitive benefits in MCI patients at 16mg per day
- MCI participants taking 16mg per day were 48% less likely to progress to dementia at 12 months and showed no significant decline over two years
- Earlier trials using doses of 69mg to 228mg per day showed no benefits, again consistent with the hormetic dose-response pattern
- The compound used in the LUCIDITY trial is HMTM, a derivative of methylene blue, not identical to it
- No methylene blue compound is currently approved as an Alzheimer's treatment
References
- Wischik CM, et al. LUCIDITY Phase III trial results. Journal of Prevention of Alzheimer's Disease. 2026.
- Hashmi MU, et al. Exploring Methylene Blue and Its Derivatives in Alzheimer's Treatment: A Comprehensive Review of Randomized Control Trials. Cureus. 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631450/
- TauRx Therapeutics. AD/PD 2024 and AD/PD 2025 conference presentations. https://taurx.com
- Alzheimer's Discovery Foundation. Methylene Blue Cognitive Vitality Research Summary. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Methylene-Blue-Cognitive-Vitality-For-Researchers.pdf
- Atamna H, et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB Journal. 2008. https://pubmed.ncbi.nlm.nih.gov/17928358/